Dipeptidyl peptidase-4 inhibitors: Anti-diabetic drugs with potential effects on cancer
Related Experiment Video
Updated: Jan 30, 2026

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells
Published on: June 30, 2023
Alaa G Almagthali1, Eman H Alkhaldi1, Afnan S Alzahrani1
1Pharm D, College of Pharmacy, Taif University, Taif, Saudi Arabia.
Abstract:
Dipeptidyl peptidase (DPP- 4) inhibitors belong to the oral antidiabetic drugs. They are used for the treatment of Type 2 Diabetes mellitus. DPP-4 is an enzyme which puts down the action of hormone, incretin. Incretins belong to the group of hypoglycaemic gastrointestinal hormones. Some studies show that DPP-4 inhibitors causes cancer and some study show that they have anticancer property. This review sheds light on the role of the different types of DPP-4 inhibitors in cancer therapy.
Related Concept Videos
Dipeptidyl Peptidase 4 Inhibitors
Psychoneuroimmunology: Diabetes and Cancer
Antihypertensive Drugs: Direct Renin Inhibitors
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

